

Auxellence announces Listing on Frankfurt Stock Exchange and Corporate Update

VANCOUVER, BC, Friday, June 5, 2015 – Auxellence Health Corporation (CSE:AID, OTCQB: AXHLF, FRANKFURT: AUH, WKN: A14SUT) is pleased to announce that its common shares has been approved for trading on under the symbol "AUH"; WKN: A14SUT on the Quotation Board of the Frankfurt Stock Exchange, also known as Borse Frankfurt (FWB).

Auxellence has had a very busy year to date and would like to provide the following update:

2015 Corporate Update

- Auxellence previously announced that it had entered into an agreement with a venture capital firm (Intrinsic Venture Corp."Intrinsic") to participate in debt and equity financing of the Company and to assist in developing a United States rollout strategy for the Company's Health Technology and System. The company is appreciative of the efforts of Intrinsic and the funding provided, however terms within this agreement have expired and the company has now terminated the agreement with the agreement not fully completed. The company is in discussions with Intrinsic to determine a course of action to continue to work with management of Intrinsic.
- Auxellence previously announced that it had signed a USA Distribution Agreement. –
 This agreement has not been completed and has now been terminated. The company is
 focusing on its Canadian roll-out.
- Auxellence continues to complete the previously approved Plan of Arrangement from Supreme Court of BC. The company expects to complete all push-out shares for the various companies from the Plan of Arrangement by the end of June 2015. An updated news release will be issued upon completion.
- Auxellence had acquired the intellectual property underlying the company's interactive health care system (subject to certain terms and conditions). – The company is negotiating certain funding terms that have not been fulfilled.
- Auxellence is in negotiations to extend terms within the General Service Agreement (GSA) with its primary medical device manufacturer and commercial operator as the company.
- The company continues to review opportunities in the medical monitoring, diagnostics
 and therapeutics fields, and hopes to be able to bring significant value propositions to
 potential customers and shareholders. Management expects to provide further updates
 in the near future and in the meantime continues to work on behalf of the shareholders.



Contact: Sydney Au, CEO Auxellence Health Corporation Email: ceo@auxellence.com

Phone: (604) 780-3311

About Auxellence Health Corporation (CSE:AID)

Auxellence is a technology company engaged in the provision of medical monitoring, diagnostics, therapeutics and biomedical online services for common health problems. The company offers an extensive platform for physiologically interactive computing supporting therapeutic-diagnostic (theranostic) devices, expert systems, and recommender applications for personal health management. The initial focus is on weight management and skin conditions.

Disclaimer for Forward-Looking Information

Statements in this press release regarding the Company which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Such information can generally be identified by the use of forwarding-looking wording such as "may", "will", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to factors. The Company does not intend to update any changes to such statements, except as required by law. Although Management believes that the expectations represented in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

THIS PRESS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES